Prothena Corporation plc

+0.37 (+0.77%)
Regulatory, Earnings Announcements

Prothena Reports Topline Early-Stage Trial Results Of Alzheimer’s Disease Treatment

Published: 01/31/2023 22:49 GMT
Prothena Corporation plc (PRTA) - Prothena Reports Topline Phase 1 Single Ascending Dose Study Results of Prx005, a Novel Anti-mtbr-tau Antibody for the Potential Treatment of Alzheimer’s Disease.
Prothena Corporation Plc - Single Doses of Prx005 Across Three Dose Cohorts Were Generally Safe and Well Tolerated, Meeting Primary Objective of Study.
Prothena - Phase 1 Multiple Ascending Dose (mad) Portion of Study is Ongoing; Topline Results Expected by Year End.
Revenue is expected to be $9.83 Million
Adjusted EPS is expected to be -$0.87

Next Quarter Revenue Guidance is expected to be $9.83 Million
Next Quarter EPS Guidance is expected to be -$0.93

More details on our Analysts Page.